SEC Comment Letter 0000000000-23-006515 to X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc
Date: June 16, 2023 · CIK: 0001501697 · Accession: 0000000000-23-006515
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272551
Letter
United States securities and exchange commission logo June 16, 2023 Adam Mostafa Chief Financial Officer X4 Pharmaceuticals, Inc 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 Re:X4 Pharmaceuticals, Inc Registration Statement on Form S-3 Filed June 9, 2023 File No. 333-272551 Dear Adam Mostafa: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
June 16, 2023
Adam Mostafa
Chief Financial Officer
X4 Pharmaceuticals, Inc
61 North Beacon Street, 4th Floor
Boston, Massachusetts 02134
Re:X4 Pharmaceuticals, Inc
Registration Statement on Form S-3
Filed June 9, 2023
File No. 333-272551
Dear Adam Mostafa:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences